Biologic predictors in follicular lymphoma: Importance of markers of immune response
Authors:
- 1 January 2007
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (12) , 2403-2411
Abstract
We sought to identify biologic indicators of prognosis in a series of 94 follicular lymphoma (FL) patients, focusing on markers of the host immune response as well as of B-cell maturation. Immune response was assessed with immunostains for CD68 (for lymphoma-associated macrophages, LAMs) and FOXP3 (regulatory T-cells). Lymphoma cells were evaluated for expression of bcl-2, CD10, and MUM-1. Clinical data were obtained for FLIPI, presence of bulky disease, presence of B-symptoms, treatment, and overall survival (OS). For the 69 initially treated patients, extrafollicular CD68+ cells (ef-CD68) and follicular FOXP3+ cells (f-FOXP3) were associated with shorter OS, while receipt of rituximab was associated with longer OS. Multivariable analysis showed ef-CD68 was the only independent factor associated with shorter OS. In subset analysis, ef-CD68 remained statistically significant in rituximab-naïve but not rituximab-treated patients. We confirm the importance of LAMs and f-FOXP3 as predictors of OS in FL.Keywords
This publication has 40 references indexed in Scilit:
- High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphomaBlood, 2006
- Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)Blood, 2005
- Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune CellsNew England Journal of Medicine, 2004
- Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progressionAnnals of Oncology, 2004
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Expression of bcl-6 and CD10 Protein Is Associated With Longer Overall Survival and Time to Treatment Failure in Follicular LymphomaAmerican Journal of Clinical Pathology, 2004
- A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survivalBlood, 2003
- Prognostic Significance of Ki-67 Nuclear Proliferative Antigen, bcl-2 Protein, and p53 Expression in Follicular and Diffuse Large B-Cell LymphomaMedical Oncology, 2001
- Clinical Significance of the t(14;18) AndBCL2Overexpression in Follicular Large Cell LymphomaLeukemia & Lymphoma, 2000
- Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphomaCancer, 1995